Intralesional and systemic rituximab in the treatment of primary cutaneous B‐cell lymphoma
نویسندگان
چکیده
Background Primary cutaneous B-cell lymphoma (PCBCL) is a group of lymphomas the skin containing primary follicle centre (PCFCL) and marginal zone lymphoma/lymphoproliferative disorder (PCMZL), which are indolent, diffuse large lymphoma, leg type (PCDLBCL-LT), aggressive. Objectives To evaluate treatment outcomes between PCBCL subtypes after with rituximab to compare efficacy intralesional against systemic in indolent subtypes. Methods A search for patients diagnosed treated (systemic or intralesional) across all Mayo Clinic sites was performed, yielding 39 patients. Results Eight had PCFCL (six intralesionally two systemically), 11 PCMZL (four intralesional, eight one dual-treated) 20 PCDLBCL-LT (all systemic). The average age at diagnosis 62.1 years (SD = 15.1), follow-up 1852.6 days 1473.2). 69.2% any form experienced complete response (100% PCFCL, 81.8% 50% PCDLBCL-LT). When comparing three subtypes, significant difference seen overall (p 0.022), progressive disease rates 0.015), but not retreatment 0.440), time 0.757), recurrence 0.907) survival 0.093). In no 1.000), 0.650), 0.650) 0.724) observed. Conclusions This study suggests that rituximab, as therapy therapy, effective management PCBCL, should be considered before more aggressive disease.
منابع مشابه
Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma
CBCL: cutaneous B-cell lymphoma INTRODUCTION Cutaneous B-cell lymphomas (CBCL) are a heterogeneous group of lymphoproliferative diseases that can be classified in 2 broad categories: primary and secondary. The latter implies a systemic lymphoproliferative disease that causes visible cutaneous lesions. Numerous articles regarding the diagnosis and treatment of primary CBCL have been published. H...
متن کاملIntralesional Rituximab Treatment for Primary Cutaneous B-cell Lymphoma: Nine Finnish Cases.
متن کامل
[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Cutaneous follicular center B-cell lymphomas are indolent tumors characterized by the presence of neoplastic follicular center cells. They contain a mixture of centrocytes with a variable number of centroblasts. The tumor is usually treated by surgery or radiotherapy, although other treatments may be used such as interferon-alpha, chemotherapy, and biological agents (rituximab). Rituximab is a ...
متن کاملIntralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
BACKGROUND We report the use of a new treatment modality in 2 patients with primary cutaneous B-cell lymphoma. In a 58-year-old woman with progressive nodular lesions on the scalp and face, several treatment attempts either failed or could not be used because of severe adverse effects and underlying epilepsy. The patient declined radiotherapy. A 30-year-old man presented with recurrence of tumo...
متن کاملRituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cuta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JEADV Clinical Practice
سال: 2023
ISSN: ['2768-6566']
DOI: https://doi.org/10.1002/jvc2.205